Sibold William John sold $6.2M of MDGL

UBS raised its price target for Madrigal Pharmaceuticals (MDGL) to $735 from $669, citing a higher probability of success for its F4 program. The stock is currently trading at $452.12, down 22% year-to-date, but analysts maintain a Strong Buy consensus. The company reported Q2 2026 net sales of $364.3 million for Rezdiffra, up 71% year-over-year, but faced a wider net loss and rising expenses. Multiple analysts have adjusted their price targets and ratings for MDGL.

Madrigal Pharmaceuticals (MDGL) published a secondary analysis from its Phase 3 MAESTRO-NASH trial, showing Rezdiffra's effectiveness across genetic variants in MASH patients. The study found consistent fibrosis improvement and MASH resolution in treated groups. The company plans to consult with the FDA on a Phase 2 combination trial with Rezdiffra and MGL-0795. Rezdiffra is approved for MASH treatment and is being tested for cirrhosis.

Goldman Sachs initiated coverage on Madrigal Pharmaceuticals (MDGL) with a Buy rating and $704 price target. The company's Rezdiffra drug generated $1.3B in 12-month revenue with 91% gross margins. Q2 2026 revenue grew 71% YoY to $364.3M, exceeding estimates. Analysts maintain positive ratings despite net losses and rising expenses.

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates • Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% • As of June 30, 2026, more than 49,000 patient

Portman David J. purchased 3,149,470 indirectly-held shares of LeonaBio, Inc. (LONA) at $3149.47 on 2026-10-26.

KAMFAR RAMIN purchased 178,677 indirectly-held shares of Bluerock Private Real Estate Fund (BPRE) at an average of $12.48 ($12.48–$12.48, $2.23M total) across 2 trades over 2026-10-26 to 2026-10-27.